Overview Clinical efficacy Pharmacokinetic and Bioavailability Drugs interaction Biological effects References
ChemicalBook > CAS DataBase List > Matrine

Matrine

Overview Clinical efficacy Pharmacokinetic and Bioavailability Drugs interaction Biological effects References
Product Name
Matrine
CAS No.
519-02-8
Chemical Name
Matrine
Synonyms
Vegard;MATRINE;MATRENE;Matrines;MATRINIUM;MATRINE(P);(+)-MATRINE;Matrine CRS;MASSMARK 1621;alpha-matrine
CBNumber
CB8284723
Molecular Formula
C15H24N2O
Formula Weight
248.36
MOL File
519-02-8.mol
More
Less

Matrine Property

Melting point:
77 C
alpha 
D20 +38° (alc)
Boiling point:
86-88C/2,5Torr
Density 
1,191g/cm
refractive index 
1,536
storage temp. 
2-8°C
pka
9.47±0.20(Predicted)
Merck 
14,5759
CAS DataBase Reference
519-02-8(CAS DataBase Reference)
NIST Chemistry Reference
Matrine(519-02-8)
More
Less

Safety

Hazard Codes 
Xn
Risk Statements 
20/21/22-37/38-41-48-22
Safety Statements 
22-26-36/37/39-45-36/37
WGK Germany 
3
RTECS 
OQ1754000
HS Code 
13021990
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Warning
Hazard statements

H302Harmful if swallowed

H319Causes serious eye irritation

Precautionary statements

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

More
Less

N-Bromosuccinimide Price

Sigma-Aldrich
Product number
M5319
Product name
Matrine
Packaging
100mg
Price
$295
Updated
2021/03/22
Sigma-Aldrich
Product number
M5319
Product name
Matrine
Packaging
500mg
Price
$659
Updated
2021/03/22
TCI Chemical
Product number
M2120
Product name
Matrine
Packaging
1G
Price
$633
Updated
2021/03/22
TCI Chemical
Product number
M2120
Product name
Matrine
Packaging
200MG
Price
$180
Updated
2021/03/22
Cayman Chemical
Product number
22901
Product name
Matrine
Purity
≥98%
Packaging
250mg
Price
$189
Updated
2021/03/22
More
Less

Matrine Chemical Properties,Usage,Production

Overview

Matrine (MT) is a kind of alkaloid components found in the roots of Sophora species, having various pharmacological activities and are demonstrated to have anti-inflammatory, anti-allergic, anti-virus, antifibrotic, and cardiovascular protective effects. It is recently proved to have anti-cancer potentials, such as inhibiting cancer cell proliferation, inducing cell cycle arrest, accelerating apoptosis, restraining angiogenesis, inducing cell differentiation, inhibiting cancer metastasis and invasion, reversing multidrug resistance, and preventing or reducing chemotherapy- or radiotherapy-induced toxicity when combined with other chemotherapeutic drugs.

Clinical efficacy

Sophora root, which is a traditional herb medicine found in China, Japan and some European countries, is the dried root of Sophora flavescens Aiton (Leguminosae) and includes matrine (MT), a major tetracycloquinolizindine alkaloids, as its primary components (chemical structure are shown in Fig. 1)[1–3]. It was reported that MT exhibit many biological activities and possess a wide range of pharmacological effects, such as anti-inflammation, anti-arrhythmia, anti-virus, antifibrotic, anti-allergy, analgesic, and immunosuppression[4], leading to wide clinical use in the treatment of viral hepatitis, liver fibrosis, cardiac arrhythmia, skin diseases, and autoimmune disease in China. Recently, MT has been extensively studied, for their cancer chemopreventive potential against various cancers, for instance gastric cancer, lung cancer, breast cancer, hepatocellular carcinoma, pancreatic cancer, melanoma, leukemia, cervix cancer, and osteosarcoma[5-7]. However, the precise mechanism underlying the anticancer activity of MT is largely unknown. Therefore, in the present study, we focus on the current studies regarding various aspects of MT as they relate to their efficacy against cancer and associated molecular mechanisms.

Figure 1 the chemical structure of matrine

Pharmacokinetic and Bioavailability

Within the past decade, several research groups have evaluated the pharmacokinetics of MT an extracts in vivo. Zhang et al. investigated the pharmacokinetics of MT in human plasma by liquid chromatography/tandem mass spectrometry (LC/MS/MS) method. After oral administration of MT soft gelatin capsules 100, 200 and 400 mg, as the major pharmacokinetic parameters of MT, the area under the plasma concentration-time curve (AUC) and the maximum plasma concentrations (Cmax) increased in proportion to dose increase, but the time of occurrence (Tmax) had no apparent change as the dose ascended. So they draw a conclusion that MT had linear pharmacokinetic trends in healthy Chinese volunteers[8]. This result could be used as a suitable reference in clinical practice. In order to enhance the bioavailability of MT, Ruan et al. prepared the matrine phospholipid complex (MPC) by solvent evaporation method. And after oral administration, the absolute bioavailability of MT was drastically increased from 25 to 84.6 % by the formation of MPC, with an outstanding relative bioavailability of 338 %. This result suggests MPC possesses great potential for clinical application. These two studies indicate a bright way to improve the clinical efficacy of MT. Fan et al. determined a specific and sensitive liquid chromatography mass spectrometry (LC-MS) method of oxymatrine (OMT) and its active metabolite MT after administration of OMT oral solution in human plasma. The test showed only part of OMT is absorbed by the gastrointestinal tract while most of it was absorbed after arrived in the intestines and quickly transformed into MT, which in turn plays a very good role during the treatment of liver injuries[9]. This result showed OMT oral solution had good absorption, quick effect and long acting time. Wu et al. conducted a study of OMT and its metabolite MT in human plasma after i.v. Infusion administration of 600 mg of OMT in 100 ml of 5 % glucose. They found the plasma concentration time profiles of OMT and MT obtained were best fitted with two-compartment and one-compartment models, respectively, and the Cmax, Tmax, AUC0–t were (20,519±7,581) and (247±45) ng/ml, (0.5±0.1) and (5.6±1.7) h, (20,360±5,205) and (3,817±610) ng h/ml, respectively.

Drugs interaction

Recently, drug–drug interactions, which can manifest as impaired drug efficacy and/or enhanced toxicity in combination use of natural products and prescribed drugs, have been documented in both pre-clinical and clinical investigations [10]. MT displays the synergistic effect with the anti-cancer agents trichostatin A (a histone deacetylase inhibitor), celecoxib (a cyclooxygenase-2 inhibitor) and rosiglitazone against the tumor proliferation and VEGF secretion. Hu et al. reported that the inhibitory effect of combined MT and 5-FU is superior to MT or 5-FU alone on the growth of transplanted human gastric cancer in nude mice. They also found combining MT and 5-FU can increase the inhibitory effect on proliferative hemopoietic bone marrow cells and does not affect the resting bone marrow stem cells[11]. Yang et al. showed that, in patients with non-small cell lung cancer, the effect of intra-operative pleural perfusion with cisplatin plus MT is superior to cisplatin alone. They concluded that pleural perfusion chemotherapy with cisplatin plus MT might be considered as an early-phase intervention against probable tumor metastasis[12]. All these studies indicated that MT could enhance the efficacy of many anticancer drugs by drug–drug interactions.

Biological effects

Anti-cancer
Carcinogenesis is a multistep process that can be activated by altered expression of onco-proteins and transcriptional factors involved in cell proliferation, cell cycle regulation, apoptosis, angiogenesis, cell differentiation, cell invasion, and metastasis[13]. Deregulated cell cycle progression and apoptosis together with increased proliferation capacity, angiogenic potential, invasion, and metastasis have been described as symbol of cancer. Accordingly, the agents that could target one or more of these processes should be ideal cancer chemopreventive agents. MT exerts their anti-cancer activities by various channels, mainly manifested in inhibiting cancer cell proliferation, inducing cell cycle arrest and differentiation, accelerating apoptosis, restraining agiogenesis, inhibiting metastasis and invasion, reversing multidrug resistance and preventing or reducing chemotherapyand radiotherapy-induced toxicity[14].
MT and OMT treatments have been shown to inhibit the proliferation of tumor cells in various cancers, including gastric cancer (MKN45 and SGC-7901), breast cancer (MDA-MB-231), hepatoma (SMMC-7721), colon cancer (SW1116), melanoma (M21), glioma (C6), osteosarcoma (UMR-108), pancreatic cancer (PANC-1), and leukemia (U937) in a dose-dependent manner[15-17].

Modulation of cell cycle progression
MT could inhibit proliferation of cells by inhibiting cell cycle progression at different phases of the cell cycle, such as an increase of G0/G1 phase and a decrease of S phase in human hepatoma cells. Studies from Zhao et al. demonstrated that MT induces G1 phase arrest in human retinoblastoma Y79, WERI-RB1, and SO-RB50 cells, and the molecular mechanisms are associated with up-regulation of CDK inhibitors p21 and p27 and down-regulation of cyclin D1 protein[18]. MT induces significant G0/G1 accumulation and G2/M depletion by increasing p21 mRNA and decreasing cyclin D1 mRNA. Furthermore, MT can result in cell cycle arrest in G0/G1 phase in gallbladder carcinoma GBC-SD cells and induce cell apoptosis by down-regulation of cyclin E expression. It is reported that the E2F family of transcription factors control the G1/S transition in eukaryotic cells. MT treatment could obviously up-regulate the expression of E2F1, as well as down-regulate Rb, an inhibitor of E2F-1 activity, and finally lead to cell apoptosis in K562 cells [19-21].

Induction of cell apoptosis
Apoptosis is a ubiquitous and highly regulated mechanism by which cells undergo programmed cell death[22]. Cancer cell is resistant to apoptosis. Studies have reported that MT exerts anti-cancer effects by inducing apoptosis in different type of cancers. Liang et al. showed that MT induces apoptotic cell death in human osteosarcoma cells by activating of caspase-3, caspase-8 and caspase-9 and increasing the expression of factor associated suicide/factor-associated suicide ligand (Fas/FasL). This major caspase-dependent pathway plays an important role in regulation of cell apoptosis. In retinoblastoma cells human breast cancer MDA-MB-231 cells[23], MT induces apoptosis by decreasing the expression of antiapoptotic protein Bcl-2 and increasing expression of proapoptotic protein Bax. MT causes apoptosis in V600EBRAF harboring M21 cells by inhibiting the PI3K/Akt pathway that is associated with activation of phosphatase and tensin homolog deleted on chromosome 10 (PTEN)[24]. It has been shown that MT induces apoptosis in human acute myeloid leukemia cells by collapsing the mitochondrial membrane potential, inducing the cytochrome C release from mitochondria, reducing the ratio of Bcl-2/Bax, increasing activity of caspase-3, and decreasing the levels of phosphorylated Akt and phosphorylated ERK1/2[25].

Anti-angiogenic activity
Angiogenesis is a physiological process of microvascular generation and growth, and plays an important role in the growth and spread of cancer[26]. MT exerts its anti-angiogenic activity in human NSCLC A549 cells by reducing the secretion of vascular endothelial growth factor (VEGF), a key regulator of normal and abnormal angiogenesis[27]. Chen et al. demonstrated that OMT inhibits the growth and survival of human pancreatic cancer PANC-1 cells by inhibiting capillary tube formation. The molecular events associated with these effects include a decrease of
NF-κB mRNA and NF-κB p65 protein, which has been reported associated with angiogenesis[28], and a down-regulation of VEGF levels. Qu et al. found, after administration of MT, that the solid tumors in H22 tumor-bearing mice were inhibited in a dose-response relationship and the quality of life were improved; the anti-cancer effect may be related to the down-regulation of VEGF[29].

Induction of autophagy
Autophagy, an important cell death process besides apoptosis, regulates cell death in both physiological and pathophysiological conditions. The genetic or pharmacological inhibition of autophagy can sensitize cancer cells to various cancer therapies[30]. Therefore, the inhibition of autophagy is therapeutically beneficial for anticancer therapies. After treatment with MT, the HepG2 hepatoma cells exhibited remarkable morphological changes, including an appearance of abundant autophagic vacuoles (AVs) of varied sizes, and an increased expression of Beclin 1, which is the first identified mammalian gene to induce autophagy[31]. In addition, 3MA, an inhibitor that blocks autophagic sequestration, prevented the accumulation of Avs. After treatment with MT, the massive AVs in SGC7901 gastric cancer cells and C6 glioma cells were observed under transmission electron microscopy, and the expression of BNIP1, BNIP2, NNIP3 andDRPK1 were all increased in C6 glioma cells. Recently, Wang et al. observed that MT promotes the accumulation of AVs accompanied by attenuation of proteinase activity in lysosomes. Meanwhile, MT alters the pH environment of lysosomes, thereby resulting in an inhibition of trafficking and proteolytic activation of lysosomal enzymes[32].

Induction of cell differentiation
It is reported that MT has an ability to induce cell differentiation in human erythro-leukemia K562 cell line accompanied by loss of telomerase activity[33]. MT treatment up-regulates the expression of p27kip1, a potential downstream molecule in cell differentiation and apoptosis pathways, and induces K562 cells to exhibit apoptotic characteristics, demonstrating that MT-induced erythroid differentiation in K562 cells is associated with cell apoptosis[34].

References

  1. Lai JP, et al Anal Bioanal Chem. 2003;375:264–9.
  2. Liu JY, et al Int Immunopharmacol. 2007;7:816–23.
  3. Sun J, et al J Sep Sci. 2009;32:2043–50.
  4. Kan QC, et al Immunol Res. 2013;56: 189–96.
  5. Zhang S, et al PloS One. 2012;7: e46853.
  6. Zhang L, et al Eur J Pharmacol. 2007;563:69–76.
  7. Yan F, et al Tumour Biol. 2013;34:2135–40.
  8. Zhang XL, et al J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877:3253–6.
  9. Fan R, et al Fitoterapia. 2013;89:271–7.
  10. Kennedy DA, et al Expert Opin Drug Saf. 2010;9(1):79–124.
  11. Hu MJ, et al Chin J Dig Dis. 2005;6(2):68–71.
  12. Yang CL, et al Med Oncol. 2012;29(2):574–81.
  13. Ramasamy K, et al Cancer Lett. 2008;269:352–62.
  14. Sun Q, et al Afr J Tradit Complement Altern Med. 2012;9:178–88.
  15. Zhang S,Qi J, et al Mol Biol Rep. 2009;36:791–9.
  16. Ling Q, et al J Exp Clin Cancer Res. 2011;30:66.
  17. Liu XS, et al Planta Med. 2006;72:501–6.
  18. Zhao B, et al Graefes Arch Clin Exp Ophthalmol. 2012;250:897–905.
  19. Zhang Z, et al Phytother Res. 2012;26:932–7.
  20. Harbour JW, et al Genes Dev. 2000;14:2393–409.
  21. Jiang H, et al Eur J Pharmacol. 2007;559:98-108
  22. Degterev A, et al Oncogene. 2003;22:8543–67.
  23. Yu P, et al Cytotechnology. 2009;59:219–29.
  24. Jin H, et al Int J Mol Sci. 2013;14:16040–57.
  25. Zhang S, et al PloS One. 2012;7: e46853.
  26. Maheshwari RK et al Life Sci. 2006;78: 2081–7.
  27. Lee TH, et al PLoS Med. 2007;4:e186.
  28. North S, et al Cancer Lett. 2005;218:1–14.
  29. Qu F, et al Anti-tumor Pharmacy (China). 2011;1:374–8.
  30. Yang ZJ, et al Mol Cancer Ther. 2011;10:1533–41.
  31. Liang XH, et al Nature. 1999;402:672–6.
  32. Wang Z, et al Carcinogenesis. 2013;34:128–38.
  33. Zhang LP, et al Leuk Res. 2001;25:793–800.
  34. Fukuchi Y, et al Oncol Rep. 2006;16:1099–103.

Chemical Properties

White solid

Uses

antifungal, nematocide

Matrine Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Matrine Suppliers

Shanghai Standard Technology Co.,Ltd.
Tel
+86 (21) 5132-0033-8655/18939960377
Fax
+86 (21) 5132-0077
Email
lxxu@nature-standard.com
Country
China
ProdList
1695
Advantage
58
Shaanxi billion Kang Long biological technology co., LTD
Tel
Fax
4009024560
Email
997832940@qq.com
Country
China
ProdList
289
Advantage
58
Hunan delilai biotechnology co., ltd
Tel
13762766818
Email
deruilaibio@163.com
Country
CHINA
ProdList
68
Advantage
58
Shaanxi Pioneer Biotech Co.,Ltd
Tel
029-86107037-8021
Email
sales@pioneerbiotech.com
Country
China
ProdList
334
Advantage
58
Shaanxi Wendi Biological Technology Co., Ltd.
Tel
Email
bjsydsw@163.com
Country
China
ProdList
108
Advantage
58
Yunnan Lilian biology Co., Ltd
Tel
Email
3282217861@qq.com
Country
China
ProdList
27
Advantage
58
Hubei Shishun Biotechnology Co. Ltd
Tel
027-59223025- ;027-59223025-
Fax
027-59223025
Email
1400818899@qq.com;1718480011@qq.com
Country
China
ProdList
9118
Advantage
58
Hubei Wande Chemical Co., Ltd
Tel
027-59210159- ;027-59210159-
Fax
027-59210159
Email
1148280033@qq.com;1148380022@qq.com
Country
China
ProdList
9079
Advantage
58
J & K SCIENTIFIC LTD.
Tel
010-82848833- ;010-82848833-
Fax
86-10-82849933
Email
jkinfo@jkchemical.com;market6@jkchemical.com
Country
China
ProdList
96500
Advantage
76
Meryer (Shanghai) Chemical Technology Co., Ltd.
Tel
21-61259100-
Fax
86-21-61259102
Email
sh@meryer.com
Country
China
ProdList
40264
Advantage
62
Chembest Research Laboratories Limited
Tel
021-20908456-
Fax
021-58180499
Email
sales@BioChemBest.com
Country
China
ProdList
5948
Advantage
61
Energy Chemical
Tel
021-58432009-
Fax
021-58436166
Email
sales8178@energy-chemical.com
Country
China
ProdList
42923
Advantage
61
Shanghai Hanhong Scientific Co.,Ltd.
Tel
021-54306202- ; ;
Fax
+86-21-64545202
Email
jerry.ma@hanhonggroup.com;jerry.ma@hanhonggroup.com;jerry.ma@hanhonggroup.com
Country
China
ProdList
43255
Advantage
64
China DongFan Chemical Co.,LTD
Tel
86-0571-85151182
Fax
86-0571-85151182
Email
sales@dongfan-chem.com
Country
China
ProdList
5702
Advantage
66
Chengdu XiYa Chemical Technology Co., Ltd.
Tel
;
Fax
0539-6365991
Email
sale@xiyashiji.com;3007716753@qq.com
Country
China
ProdList
10578
Advantage
57
BEST-REAGENT
Tel
400-1166-196;028-84555506- ;028-84555506-
Email
cdhxsj@163.com;1955352637@qq.com;cdhxsj@163.com
Country
China
ProdList
11718
Advantage
57
China Langchem Inc.
Tel
0086-21-58956006,021-38701807;021-58950017
Fax
0086-21-58956100
Email
sales@langchem.com
Country
China
ProdList
7833
Advantage
57
Tianjin heowns Biochemical Technology Co., Ltd.
Tel
400 638 7771
Email
sales@heowns.com
Country
China
ProdList
14457
Advantage
57
Sinopharm Chemical Reagent Co,Ltd.
Tel
86-21-63210123
Fax
86-21-63290778 86-21-63218885
Email
sj_scrc@sinopharm.com
Country
China
ProdList
9844
Advantage
79
Hubei YuanCheng Pharmaceutical Co., Ltd.
Tel
18062666904
Fax
QQ:2355880546
Email
wyy01@ycphar.com
Country
China
ProdList
670
Advantage
65
Aktin Chemicals, Inc.
Tel
86-28-85159085
Fax
86-28-85152372
Email
info@aktinchem.com
Country
China
ProdList
297
Advantage
62
Shenzhen Sungening Bio-Tech Co., Ltd
Tel
+86-0755-89668383
Fax
+86-0755-89594066/4038
Email
sales@sungening.com
Country
China
ProdList
1319
Advantage
65
Dalian Meilun Biotech Co., Ltd.
Tel
0411-66864596- ;0411-66864952-
Email
sales@meilune.com;sales@meilune.com
Country
China
ProdList
3573
Advantage
58
BioBioPha Co., Ltd.
Tel
0871-65217109-
Fax
0871-65215563
Email
sales@mail.biobiopha.com
Country
China
ProdList
5688
Advantage
65
ShangHai YuanYe Biotechnology Co., Ltd.
Tel
021-61312847-
Fax
021-55068248
Email
3008007399@qq.com
Country
China
ProdList
4995
Advantage
60
Chengdu Ai Keda Chemical Technology Co., Ltd.
Tel
028-85911938-
Fax
028-86757656
Email
800078821@qq.com
Country
China
ProdList
9750
Advantage
55
Chengdu Biopurify Phytochemicals Ltd.
Tel
028-82633397
Fax
+86-28-82633165
Email
sales03@biopurify.com
Country
China
ProdList
1990
Advantage
60
Chengdu Climax Biotech Co., Ltd.
Tel
028-83311324 QQ:1278112614
Fax
028-83311324
Email
climaxbiotech@gmail.com
Country
China
ProdList
925
Advantage
58
Shanghai Winherb Medical Technology Co., Ltd.
Tel
136-81877033- ;
Fax
QQ:190129269
Email
winherb@126.com;2702713455@qq.com
Country
China
ProdList
1003
Advantage
58
Shanghai civi chemical technology co.,Ltd
Tel
86-21-34053660;34053661
Fax
86-21-34053661
Email
sale@labgogo.com
Country
China
ProdList
9886
Advantage
52
XI'AN KPC-CN BIOLOGICAL TECHNOLOGY CO.,LTD.
Tel
86-029-85456576
Fax
86-029-85456576-808
Email
daisy_wang@vip.163.com
Country
China
ProdList
293
Advantage
55
Nanjing Spring & Autumn Biological Engineering Co., Ltd.
Tel
025-84430028-
Email
sale02@cqherb.com
Country
China
ProdList
253
Advantage
59
Beijing HuaMeiHuLiBiological Chemical
Tel
010-56205725;010-86181995
Fax
010-65763397
Email
waley188@sohu.com
Country
China
ProdList
12341
Advantage
58
Haoyuan Chemexpress Co., Ltd.
Tel
86-21-58998985
Fax
(86) 21-58955996
Email
apisales@chemexpress.com.cn
Country
China
ProdList
7557
Advantage
61
Cheng Du Micxy Chemical Co.,Ltd
Tel
028-85632863-
Fax
028-85632863
Email
sales@micxy.com;
Country
China
ProdList
13065
Advantage
58
9ding chemical ( Shanghai) Limited
Tel
4009209199
Fax
86-021-52271987
Email
sales@9dingchem.com
Country
China
ProdList
22541
Advantage
55
Shanghai Aladdin Bio-Chem Technology Co.,LTD
Tel
021-20337333-801
Fax
021-50323701
Email
market@aladdin-e.com
Country
China
ProdList
24980
Advantage
65
The future of Shanghai Industrial Co., Ltd.
Tel
021-61552785
Fax
021-55660885
Email
sales@shshiji.com
Country
China
ProdList
9542
Advantage
55
Shanghai Ruji Biology Technology Co., Ltd.
Tel
+86-21-65211385-8001 36031160
Fax
+86-21-65211385-8004
Email
sales@shruji.com
Country
China
ProdList
3228
Advantage
55
Shanghai Tauto Biotech Co., Ltd.
Tel
021-51320588
Fax
0086-21-51320502
Email
tauto@tautobiotech.com
Country
China
ProdList
3582
Advantage
66
Guangzhou Isun Pharmaceutical Co., Ltd
Tel
020-39119399-
Fax
020-39119999
Email
isunpharm@qq.com
Country
China
ProdList
4575
Advantage
55
Nanjing Sunlida Biological Technology Co., Ltd.
Tel
025-57798810- ;025-57798810-
Fax
025-57019371
Email
sales@sunlidabio.com;sales@sunlidabio.com
Country
China
ProdList
3794
Advantage
55
Shanghai TaoShu Biochemical Technology Co., Ltd.
Tel
021-33632979-
Fax
021-33632979
Email
service1@targetmol.com
Country
China
ProdList
7962
Advantage
58
Shanghai TaoSu Biochemical Technology Co., Ltd.
Tel
021-33632979
Fax
021-34692979
Email
info@tsbiochem.com
Country
China
ProdList
8074
Advantage
58
Cheng Du Pufeide Biotechnology Co., Ltd.
Tel
028-82610909-
Fax
8171-1798
Email
scglp@glp-china.com
Country
China
ProdList
1055
Advantage
58
Chengdu Herbpurify Co.Ltd.
Tel
028-83353778-
Fax
086-28-85377358
Email
2355253616@qq.com
Country
China
ProdList
1099
Advantage
58
Shanghai BeiZhuo Biotech Co., Ltd.
Tel
021-61119791/13386096464
Fax
021-50190009
Email
bzswkf@foxmail.com
Country
China
ProdList
3930
Advantage
50
Shanghai Zhanshu Chemical Technology Co., Ltd
Tel
+86-21-58589556,13761042905
Fax
+86-21-58589557
Email
sales@zsuchem.com
Country
China
ProdList
413
Advantage
55
Hubei XinyuanShun Chemical Co., Ltd.
Tel
13971561712 / 13995564702 / 027-50664929
Fax
027-50664927
Email
hbeixys2001@163.com
Country
China
ProdList
3130
Advantage
55
Vientiane Tianjin Hengyuan Technology Co., Ltd.
Tel
15722085254
Fax
022-26358246
Email
phytochemical@126.com
Country
China
ProdList
813
Advantage
55
More
Less

View Lastest Price from Matrine manufacturers

Wuhan wingroup Pharmaceutical Co., Ltd
Product
Matrine 519-02-8
Price
US $3.00/KG
Min. Order
100g
Purity
99
Supply Ability
3000KGS
Release date
2021-07-12
Dideu Industries Group Limited
Product
Matrine USP/EP/BP 519-02-8
Price
US $1.10/g
Min. Order
1g
Purity
99.9%
Supply Ability
100 Tons min
Release date
2021-07-21
Anhui Rencheng Technology Co., Ltd
Product
Matrine 519-02-8
Price
US $1.00-300.00/KG
Min. Order
0.5KG
Purity
>99%
Supply Ability
20tons
Release date
2020-12-31

519-02-8, MatrineRelated Search:


  • alpha-matrine
  • SOPHOCARPIDINE
  • (+)-MATRINE
  • MATRINE
  • MATRINIUM
  • MATRENE
  • Alkaloids Sophora Flavescen
  • Matrines
  • MATRINE, 98.0% BY HPLC
  • MATRINE(P)
  • MASSMARK 1621
  • Matrine,Sophocarpidine
  • (7aα,13aR,13bα,13cα)-Dodecahydro-1H,5H,10H-dipyrido[2,1-f:3',2',1'-ij][1,6]naphthyridine-10-one
  • (7aα,13aβ,13bα,13cα)-2,3,6,7,7a,12,13,13a,13b,13c-Decahydro-1H,5H,8H-dipyrido[2,1-f:3',2',1'-ij][1,6]naphthyridine-10(11H)-one
  • Matrine,Matridin-15-one, Sophocarpidine
  • Matridin-15-one (7aS,13aR,13bR,13cS)-Dodecahydro-1H,5H,10H-dipyrido[2,1-f:3',2',1'-ij][1,6]naphthyridin-10-one
  • 7,13-diazatetracyclo[7.7.1.0^{2,7}.0^{13,17}]heptadecan-6-one
  • Matrine((+)-Matrine)
  • Matrine (alpha-matrine)
  • Matrine 519-02-8
  • Vegard
  • Matrine, froM Sophora flavescens
  • 1H,5H,10H-Dipyrido[2,1-f:3',2',1'-ij][1,6]naphthyridin-10-one, dodecahydro-, (7aS,13aR,13bR,13cS)-
  • Matridin-15-one (9CI)
  • Matrine, >=98%
  • Lepidium meyenii Walp extract
  • Matrine, 98%, from Sophora flavescens
  • Matridin-15-one Sophocarpidine
  • Matrine CRS
  • 519-02-8 Matrine Insecticide Biological Pesticides for Formosan subterranean termite
  • (7aS,13aR,13bR,13cS)-Dodecahydro-1H,5H,10H-dipyrido[2,1-f:3',2',1'-ij][1,6]naphthyridin-10-one
  • Matrine fandachem
  • Matrine Solution in Methanol, 1000μg/mL
  • (41S,7aS,13aR,13bR)-Dodecahydro-1H-dipyrido[2,1-f:3',2',1'-ij][1,6]naphthyridin-10(41H)-one
  • (41S,7aS,13aR,13bR)-dodecahydro-1H,5H,10H-dipyrido[2,1-f:3',2',1'-ij][1,6]naphthyridin-10-one
  • Rhubarb extract/emodin
  • Rhubarb Extract/ Chrysophanic acid
  • Rhubarb Extract/ Rhubarb Extrat anthraquinone
  • Matrine USP/EP/BP
  • 519-02-8
  • 26904-63-3
  • 51-92-8
  • C15H24ON2
  • chemical reagent
  • pharmaceutical intermediate
  • phytochemical
  • reference standards from Chinese medicinal herbs (TCM).
  • standardized herbal extract
  • natural product
  • herbal extract
  • Inhibitors
  • Miscellaneous Natural Products
  • Natural Plant Extract
  • Plant extract